Tony Coles is executive chairman and CEO of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Prior to Cerevel, Coles cofounded and served as CEO of Yumanity Therapeutics, where he was instrumental in establishing and advancing potential new treatments for the treatment of Parkinson’s disease and Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease). Coles continues to serve as executive chair of the board of directors of Yumanity Therapeutics.
Previously, Coles served as chair and CEO of Onyx Pharmaceuticals, Inc., which was acquired by Amgen Inc. in 2013. Prior to Onyx, he was president, CEO, and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals, Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier held several executive positions at Bristol-Myers Squibb Company and positions of increasing responsibility at Merck & Co., Inc.
Coles currently serves on the board of directors of McKesson Corporation and Regeneron and is a member of the board of trustees of Johns Hopkins University. He is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture, a member of the board of trustees of the Metropolitan Museum of Art, and a member of the Harvard Medical School Board of Fellows.
Coles was educated at Johns Hopkins University, earned a medical degree from Duke University, and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.